Homologous Recombination Deficiency (HRD) Testing in Ovarian Cancer

from Illumina Genomics Podcast · host Illumina Genomics Podcast

Isabelle Ray-Coquard, MD, PhD, explains how comprehensive genomic profiling (CGP) simultaneously provides HRD and BRCA status in ovarian cancer patients. She presents the case of a patient who benefited from CGP testing for these biomarkers and shares the recent findings of the PAOLA-1 trial.

Episode metadata supplied by the publisher feed · Published Nov 11, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

Homologous Recombination Deficiency (HRD) Testing in Ovarian Cancer

0:00 5:26

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Illumina Genomics Podcast?

This episode is 5 minutes long.

When was this Illumina Genomics Podcast episode published?

This episode was published on November 11, 2022.

Can I download this Illumina Genomics Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!